Blue Period - Features Of Senescence 30 Years After Beta-Galactosidase

Aging Theory
Therapeutic
The paper reviews the evolution of understanding cellular senescence over 30 years, emphasizing that while beta-galactosidase was an early marker, a broader set of features and the senescence-associated secretory phenotype are now recognized as crucial to its role in aging and disease.
Author

Gemini

Published

May 26, 2026

Imagine cells in your body that stop dividing but don’t die; instead, they hang around, potentially causing trouble. These are called senescent cells. Thirty years ago, scientists found that these cells often show increased activity of a particular enzyme, beta-galactosidase, which became one of the first ways to identify them. This discovery was a big step in understanding how these cells accumulate as we age.

Since then, our knowledge has expanded significantly. We now know that these senescent cells don’t just sit there; they also release a cocktail of molecules, a phenomenon known as the senescence-associated secretory phenotype (SASP). This cocktail can include inflammatory signals and other substances that can negatively affect neighboring healthy cells and contribute to various age-related diseases.

This review looks back at three decades of research, highlighting how our understanding of these ‘stalled’ cells has deepened. Beyond the initial enzyme marker, we’ve uncovered many other characteristics, from changes in cell size and internal structures to alterations in their genetic material. The paper emphasizes that while the beta-galactosidase marker was foundational, a comprehensive view of cellular senescence now involves recognizing these diverse features and the powerful impact of their secretions on the aging process and associated health issues.


Source: link to paper